Serological markers of inflammatory bowel disease phenotype and disease progression
AssigneeChildren's Hospital Medical Center
InventorsLee Denson, Bruce Colston Trapnel, Kanji Uchida
Life of this patent
Estimating the term…
Abstract
Disclosed are novel biomarkers and methods related to diagnostic tests for the detection and characterization of inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis. In particular, the instant invention relates to novel biomarkers and methods of using such biomarkers to predict disease behavior and severity, to differentiate among disease types, and to optimize selection of treatment options in individuals suspected of having an inflammatory bowel disease.
Claims17
A method for the diagnosis and treatment of an inflammatory bowel disease in a subject comprising:
- (a) measuring the concentration of anti-GM-CSF antibodies in a serum sample obtained from the subject;
- (b) diagnosing whether the subject has an inflammatory bowel disease, or the severity of an inflammatory bowel disease, based upon an increased concentration of the anti-GM-CSF antibodies in the sample as compared to the concentration of anti-GM-CSF antibodies in serum from a subject not having an inflammatory bowel disease;
- and
- (c) administering a therapy to the diagnosed subject, wherein the therapy is selected from the group consisting of an effective amount of anti-TNFα antibodies, an effective amount of GM-CSF, and surgery.
A method for the prognosis and treatment of an inflammatory bowel disease in a patient comprising:
- (a) determining the concentration of anti-GM-CSF antibodies in a serum sample obtained from the patient comprising contacting the sample with an immobilized GM-CSF;
- and
- (b) determining whether the patient has an increased risk of the inflammatory bowel disease progressing based upon increased binding of the GM-CSF to the anti-GM-CSF antibodies as compared to the binding of GM-CSF to anti-GM-CSF antibodies in a serum sample from a subject not having an inflammatory bowel disease;
- and
- (c) administering an effective amount of anti-TNFα antibodies to the patient having the increased risk of disease progression.
A method for the prognosis and targeted treatment of an inflammatory bowel disease in a patient comprising:
- (a) measuring an increased concentration of anti-GM-CSF antibodies in a serum sample obtained from the patient compared to the concentration of anti-GM-CSF antibodies in a sample from a subject not having an inflammatory bowel disease
- (b) determining whether the patient has an increased risk of inflammatory bowel disease progression when the increased concentration of anti-GM-CSF antibodies is measured;
- and
- (c) administering an effective amount of anti-TNFα antibodies to the patient having an increased risk of inflammatory bowel disease progression.
Dependencies are inferred from the claim text.